Enerisant
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Enerisant ( ; developmental code name TS-091) is an experimental drug under investigation as a potential treatment for narcolepsy. It is a member of the histamine H 3 receptor antagonist/inverse agonist class of medications.
Enerisant ( ; developmental code name TS-091) is an experimental drug under investigation as a potential treatment for narcolepsy. It is a member of the histamine H 3 receptor antagonist/inverse agonist class of medications.
Pharmacology
Pharmacodynamics
Enerisant functions as a potent and highly selective antagonist/inverse agonist of the histamine H 3 receptor. This mechanism of action is similar to that of pitolisant, a currently approved H 3 receptor antagonist/inverse agonist for narcolepsy; however, enerisant has demonstrated greater affinity and selectivity for the H 3 receptor in preclinical studies. By blocking H 3 receptors, enerisant increases histamine release from histaminergic neurons, leading to stimulation of postsynaptic histamine H 1 receptors, a key mechanism in promoting wakefulness
Pharmacokinetics
Enerisant exhibits minimal metabolism in humans and is primarily eliminated unchanged via renal excretion. After oral administration, it rapidly absorbs and exhibits dose-dependent plasma concentrations. Within 48 hours, 64.5-89.9% of the administered dose is recovered unchanged in urine. Plasma protein binding is approximately 31.0–31.7% in humans.
See also
List of investigational narcolepsy and hypersomnia drugs
References
Text derived from https://en.wikipedia.org/w/index.php?oldid=1328705051 under CC BY-SA 4.0; modifications have been made.